CD274 and non-small cell lung carcinoma: Although the differences in efficiency and survival benefits between the two groups were nonsignificant, the experimental group, particularly those with PD-L1− NSCLC, demonstrated a significant increase in progression-free survival (PFS) and overall survival (OS) [42].